Immutrin Revenue
Biotechnology Research • 
Cambridge, England, United Kingdom • 1-10 Employees
$
Immutrin revenue & valuation
| Annual revenue | $513,330 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,700,000 |
| Total funding | No funding |
Key Contact at Immutrin
Mihriban Tuna
Chief Executive Officer
Company overview
| Headquarters | Cambridge, England, United Kingdom |
| Website | |
| NAICS | 541714 |
| Employees | 1-10 |
About Immutrin
Amyloidosis is a group of rare but very serious, usually fatal diseases caused by the aggregation of body’s own proteins to form amyloid deposits in vital organs. Immutrin is a Cambridge-based biotech company that is developing the next generation antibody therapies for systemic and local amyloidosis.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
C-Suite
Entry
Senior
Employees by Department
Immutrin has 2 employees across 2 departments.
Departments
Number of employees
Funding Data
Immutrin has never raised funding before.
Sweden
Canada
Portugal
New Zealand
Spain
United States
Frequently asked questions
Immutrin is located in Cambridge, England, GB.
Immutrin generates an estimated annual revenue of $513,330. This revenue figure reflects the company's market position and business performance in its industry.
Immutrin has an estimated valuation of $1,700,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.
Immutrin has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users
